AZD5582 potently activates the NFκB pathway, but does not induce apoptosis in non-tumor cells and shows a modest off-target effect in host gene expression in CD4+ T cells treated ex vivo when compared with a stabilized Ingenol-B derivative (GSK445A) [53,54,55]. Here, NFKB1 is linked to neoplasm.